Market Place
Sourcing Support
Edgewise Announces Positive CANYON Ph 2 Trial Results for Becker
16 Dec 2024 //
BUSINESSWIRE
Edgewise to Present at Piper Sandler 36th Healthcare Conference
26 Nov 2024 //
BUSINESSWIRE
Edgewise Therapeutics Reports Q3 2024 Results & Business Highlights
07 Nov 2024 //
BUSINESSWIRE
Edgewise To Present Sevasemten For Becker At World Muscle Society
01 Oct 2024 //
BUSINESSWIRE
Edgewise Stock Up 50% On Heart Disease Drug Data
19 Sep 2024 //
FIERCE BIOTECH
Edgewise Therapeutics To Host Webcast Event For Phase 1 And Phase 2 Trials
17 Sep 2024 //
BUSINESSWIRE
Edgewise Therapeutics Reports Q2 2024 Results And Business Highlights
08 Aug 2024 //
BUSINESSWIRE
Edgewise Therapeutics At RBC Healthcare Conference May 15
10 May 2024 //
BUSINESSWIRE
Edgewise Therapeutics Q1 2024 Financials, Business Highlights
09 May 2024 //
BUSINESSWIRE
Edgewise`s begins patient dosing in phase 2 CIRRUS-HCM trial of EDG-7500
08 May 2024 //
PHARMABIZ
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
07 May 2024 //
BUSINESSWIRE
Edgewise Therapeutics begins Phase 2 trial for hypertrophic cardiomyopathy
06 May 2024 //
BUSINESSWIRE
Edgewise Gets EMA Orphan Designation for Muscular Dystrophies Drug
23 Apr 2024 //
BUSINESSWIRE
Edgewise Positive 2-Year Becker Sevasemten Topline Data
15 Apr 2024 //
BUSINESSWIRE
Edgewise Announces Upcoming Presentation at the American College of Cardiology`s
28 Mar 2024 //
BUSINESSWIRE
Edgewise to Present at the Cantor Virtual MD Symposium on April 2, 2024
27 Mar 2024 //
BUSINESSWIRE
Edgewise to Present at the Leerink Partners Global Biopharma Conference
05 Mar 2024 //
BUSINESSWIRE
Edgewise to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy
28 Feb 2024 //
BUSINESSWIRE
Edgewise Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 2024 //
BUSINESSWIRE
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506
13 Feb 2024 //
BUSINESSWIRE
Edgewise Announces Pricing of $240 Million Underwritten Offering of Common Stock
19 Jan 2024 //
BUSINESSWIRE
Edgewise Highlights 2023 Accomplishments and Anticipated Milestones for 2024
09 Jan 2024 //
BUSINESSWIRE
Edgewise boosts awareness of rare Becker muscular dystrophy
29 Dec 2023 //
ENDPTS
Edgewise to Present at the 42nd Annual J.P. Morgan Healthcare Conference
19 Dec 2023 //
BUSINESSWIRE
Edgewise Therapeutics Launches First of Its Kind Educational Website
18 Dec 2023 //
BUSINESSWIRE
Edgewise Receives Orphan Drug Designations for Its Muscular Dystrophy Program
30 Nov 2023 //
BUSINESSWIRE
Edgewise Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
BUSINESSWIRE
Edgewise Therapeutics to Present at Upcoming Investor Conferences
08 Nov 2023 //
BUSINESSWIRE
Edgewise to Present Data on EDG-7500
01 Nov 2023 //
BUSINESSWIRE
Edgewise Therapeutics Announces Expansion of their EDG-5506 Clinical Program
26 Oct 2023 //
BUSINESSWIRE
Edgewise Therapeutics to Present on EDG-5506 for Becker Muscular Dystrophy
27 Sep 2023 //
BUSINESSWIRE
Edgewise Therapeutics Announces Initiation of GRAND CANYON
26 Sep 2023 //
BUSINESSWIRE
Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500
14 Sep 2023 //
BUSINESSWIRE
Edgewise Therapeutics Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
BUSINESSWIRE
Edgewise Announces Positive Results from ARCH Open Label Study of EDG-5506
26 Jun 2023 //
BUSINESSWIRE
Edgewise Therapeutics to Present at Goldman Sachs Global Healthcare Conference
06 Jun 2023 //
BUSINESSWIRE
Edgewise Therapeutics Reports First Quarter 2023 Financial Results
11 May 2023 //
BUSINESSWIRE
Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023
21 Mar 2023 //
BUSINESSWIRE
Edgewise Therapeutics to Present on EDG-5506 for BMD, DMD
14 Mar 2023 //
BUSINESSWIRE
Edgewise Appoints Industry Veteran Jonathan C. Fox to its Board of Directors
06 Mar 2023 //
BUSINESSWIRE
Edgewise to Present at Cowen 43rd Annual Health Care Conference on March 8, 2023
01 Mar 2023 //
BUSINESSWIRE
Edgewise Therapeutics Announces Upcoming Presentation at World Congress
28 Feb 2023 //
BUSINESSWIRE
Edgewise Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results
23 Feb 2023 //
BUSINESSWIRE
Edgewise to Present at the SVB Securities Global Biopharma Conference
07 Feb 2023 //
BUSINESSWIRE
Edgewise to Present at J.P. Morgan Healthcare Conference on January 10, 2023
04 Jan 2023 //
BUSINESSWIRE
Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer
20 Dec 2022 //
BUSINESSWIRE
Edgewise Therapeutics to Present at Upcoming Investor Conferences
09 Nov 2022 //
BUSINESSWIRE
Edgewise Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506
27 Oct 2022 //
BUSINESSWIRE
Edgewise Therapeutics Announces Positive 6-Month Interim Results
13 Oct 2022 //
BUSINESSWIRE
Edgewise Therapeutics to Present on EDG-5506 for BMD, DMD
06 Oct 2022 //
BUSINESSWIRE
Edgewise Announces Closing of Upsized Public Offering of Common Stock
16 Sep 2022 //
BUSINESSWIRE
Edgewise Therapeutics Announces Proposed Offering of Common Stock
13 Sep 2022 //
BUSINESSWIRE
Edgewise Therapeutics Announces Pricing of Public Offering of Common Stock
13 Sep 2022 //
BUSINESSWIRE
Edgewise Announces Interim Results from the ARCH Open Label Study of EDG-5506
11 Sep 2022 //
BUSINESSWIRE
FDA authorises Edgewise’s Phase II duchenne muscular dystrophy trial
08 Sep 2022 //
CLINICALTRIALSARENA
Edgewise Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506
07 Sep 2022 //
BUSINESSWIRE
Edgewise Therapeutics Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
BUSINESSWIRE
Edgewise Tx Now Enrolling CANYON PII Trial of EDG-5506 in BMD
12 Jul 2022 //
BUSINESSWIRE
